ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
66,980.63
-0.15%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Monte Rosa Therapeutics Inc (GLUE)

  7. Monte Rosa Therapeutics Inc (GLUE) Noticias

GLUE

Monte Rosa Therapeutics (GLUE)

Monte Rosa Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GLUE
FechaHoraFuenteTítuloSímboloCompañía
16/05/202415:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202415:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
16/05/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public OfferingNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/05/202415:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202406:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GLUEMonte Rosa Therapeutics Inc
09/05/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
02/05/202415:01GlobeNewswire Inc.Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific OfficerNASDAQ:GLUEMonte Rosa Therapeutics Inc
14/03/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/03/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway InhibitorNASDAQ:GLUEMonte Rosa Therapeutics Inc
31/01/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
08/01/202406:15GlobeNewswire Inc.Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024NASDAQ:GLUEMonte Rosa Therapeutics Inc
04/01/202415:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
03/01/202406:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
21/11/202306:00GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Piper Sandler Healthcare ConferenceNASDAQ:GLUEMonte Rosa Therapeutics Inc
09/11/202306:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
07/11/202309:00GlobeNewswire Inc.Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/10/202315:30GlobeNewswire Inc.Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq RulesNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202306:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid TumorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
17/10/202306:00GlobeNewswire Inc.Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
18/08/202315:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/08/202316:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GLUEMonte Rosa Therapeutics Inc
10/08/202306:15GlobeNewswire Inc.Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/07/202306:30GlobeNewswire Inc.Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of DirectorsNASDAQ:GLUEMonte Rosa Therapeutics Inc
15/06/202315:43Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:GLUEMonte Rosa Therapeutics Inc
14/06/202315:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:GLUEMonte Rosa Therapeutics Inc
30/05/202315:30GlobeNewswire Inc.Monte Rosa Therapeutics to Present at Upcoming Investor and Industry ConferencesNASDAQ:GLUEMonte Rosa Therapeutics Inc
23/05/202306:30GlobeNewswire Inc.Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune DiseasesNASDAQ:GLUEMonte Rosa Therapeutics Inc
11/05/202306:30GlobeNewswire Inc.Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:GLUEMonte Rosa Therapeutics Inc
26/04/202315:09Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:GLUEMonte Rosa Therapeutics Inc
26/04/202315:07Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:GLUEMonte Rosa Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GLUE

Su Consulta Reciente

ASX
MPXN
Mustera Property
COIN
DDIMBTC
DuckDaoDime
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados